Skye Bioscience, Inc. · NASDAQ:SKYE
Skye Bioscience — Investor Presentation (February 2022)
24 slides from Skye Bioscience's investor presentation, February 2022
Slide 1: Building a Cannabinoid Platform in Ophthalmology
Building a Cannabinoid Platform in Ophthalmology Corporate Presentation February 2022 OTCQB: SKYE
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains “forward-looking statements”, including All information contained in this presentation is provided as of the statements regarding Skye Bioscience, Inc. “Skye Bioscience and/or date of the presentation and is subject to change without notice. the
Slide 3: Investment Highlights
§ Transformative new class of therapeutics INVESTMENT HIGHLIGHTS § Endocannabinoid system (ECS) shown to play a significant role in health § ECS-mediated signaling plays a role in multiple ocular indications § Solid clinical and preclinical foundation for glaucoma § Multiple human clinical trials ha
Slide 4: Building a Cannabinoid Platform in Ophthalmology
BUILDING A CANNABINOID PLATFORM IN OPHTHALMOLOGY The endocannabinoid system (ECS) is a complex signaling system which exists in all tissues and plays pivotal role in human health. ECS receptors in the eye CB1 CB2 Ocular Pathologies • Intraocular pressure • Nociception (pain) • Inflammation PPAR-ɣ •
Slide 5: Glaucoma Presents a Significant Unmet Need
GLAUCOMA PRESENTS A SIGNIFICANT UNMET NEED § 80M patients worldwide -> 110M by 2026 MARKET SHARE OF IOP-LOWERING DRUGS BY CLASS § $7B addressable market § 80% represent by generic prostaglandin analogs (latanoprost) or beta blockers (timolol) ROCK Inhibitor Carbonic Anhydrase Inhibitor Alpha Agonist
Slide 6: Pathophysiology of Glaucoma
PATHOPHYSIOLOGY OF GLAUCOMA • Disease that leads to the progressive damage of retinal ganglion cells (RGCs) that make up the optic nerve, resulting in irreversible vision loss • Key risk factor in disease progression is elevated intraocular pressure • Current available therapies aim to control IOP •
Slide 7: Scientific Evidence Shows Utility of Cannabinoids for Glaucoma
SCIENTIFIC EVIDENCE SHOWS UTILITY OF CANNABINOIDS FOR GLAUCOMA • ECS receptors, specifically CB1 receptors, are found in the tissues responsible for both fluid production (ciliary body) and drainage (trabecular meshwork, Schlemm’s canal) • THC and the CB1 receptor, specifically, have been shown to b
Slide 8: SBI-100 Advantage – Proprietary Molecule and Formulation
SBI-100 ADVANTAGE – PROPRIETARY MOLECULE AND FORMULATION Skye has developed a prodrug that allows local delivery into the eye, limiting systemic exposure and delivering THC to ocular tissue responsible for regulating IOP • Systemic administration of THC pose PK/PD challenges and other adverse effect
Slide 9: SBI-100 Demonstrated Superior IOP Lowering Compared to Standard of Care
SBI-100 HAS DEMONSTRATED SUPERIOR IOP LOWERING COMPARED TO STANDARD OF CARE 19 25 24 18 23 22 17 IOP (mmHg) IOP (mmHg) 21 16 20 SBI-100 netarsudil 19 15 latanoprost 18 SBI-100 SBI-100 + netarsudil timilol 17 netarsudil + 14 latanoprost latanoprost 16 latanoprost + SBI- 100 13 15 0 60 120 180 240 300
Slide 10: Multi-Factorial Mechanism of Action Directly Targets Disease
MULTI-FACTORIAL MECHANISM OF ACTION DIRECTLY TARGETS DISEASE • In a 3D model of human trabecular meshwork (TM) tissues (responsible for fluid drainage), THC significantly increased drainage (outflow) in both healthy and disease- simulated tissue • 10 •
Slide 11: Multi-Factorial Mechanism of Action Directly Targets Disease
MULTI-FACTORIAL MECHANISM OF ACTION DIRECTLY TARGETS DISEASE • THC treatment significantly reduced markers associated with fibrosis and inflammation, which are associated with glaucoma • Potentially disease modifying through extracellular matrix remodeling of the trabecular meshwork Healthy Diseased
Slide 12: SBI-100 – Addresses Multiple Issues with Current Treatment Options
SBI-100 – ADDRESSES MULTIPLE ISSUES WITH CURRENT TREATMENT OPTIONS ü Targets area of disease • Most drugs do not target the main site of disease-causing increased IOP, the trabecular meshwork (TM) SBI-100 • THC directly targets the TM and increases flow through the eye, as well as uveoscleral pathwa
Slide 13: Upcoming Catalysts to Advance Our Growth
SBI-100: PHASE 2 CRE UPCOMING CATALYSTS TO ADVANCE OUR GROWTH ü Q421: Pre-IND meeting with the FDA q Q122: Study protocol ATIN q Q322: Complete IND-enabling studies SBI-100: PHASE 1 q Q422: IND clearance q Q122: Completion of GLP toxicology studies q Q422: Phase 2 efficacy study initiation G VA q Q1
Slide 14: Cannabinoid Pharmaceutical Innovation Program
CANNABINOID PHARMACEUTICAL INNOVATION PROGRAM Expanding the reach of cannabinoid-based therapies
Slide 15: Unlocking the Potential of Pharmaceutical Cannabinoids
UNLOCKING THE POTENTIAL OF PHARMACEUTICAL CANNABINOIDS Decades of cannabinoid science advancements are merging Skye CPI Program: expanding novel cannabinoid with modern biotechnology techniques, creating an opportunity pharmaceutical research and development to to develop novel, valuable, clinically
Slide 16: CPIP: Developing an In Vitro Screening Platform for Ocular Diseases
CPIP: DEVELOPING AN IN VITRO SCREENING PLATFORM FOR OCULAR DISEASES IN VITRO OCULAR DISCOVERY SCREENING IN VIVO MODELS INDICATIONS Dry eye Ocular Pain & Inflammation AMD DR Uveitis • 16 •
Slide 17: Validation of Pharmaceutical Cannabinoid Approach
VALIDATION OF PHARMACEUTICAL CANNABINOID APPROACH GW Pharma Overview – Plant-Based Cannabinoid Therapies • GW demonstrated that cannabinoids are a viable and marketable class of drugs • Company’s lead product, Epidiolex, is first plant-derived cannabinoid approved in the US • Has since generated sal
Slide 18: Management Team
skKze MANAGEMENT TEAM
Slide 19: Senior Management
SENIOR MANAGEMENT Punit Dhillon Kaitlyn Arsenault, CPA Tu Diep, MSc Chief Executive Officer & Chair Chief Financial Officer Chief Development Officer • Co-founded and led OncoSec Medical, a • Over 14 years of experience in • Over 15 years of experience in research, cancer immunotherapy company, thro
Slide 20: Board of Directors
BOARD OF DIRECTORS Punit Dhillon James Heppell, LLB Keith Ward, PhD Chair Director Director • Co-founded and led OncoSec (NASDAQ: • Former Founder, CEO, Director of • Over 25 years of experience in the ONCS), a cancer immunotherapy BC Advantage Life Sciences biotech and pharmaceutical company, throu
Slide 21: Advisors
ADVISORS CLINICAL SCIENTIFIC Robert Ritch, MD Louis Pasquale, MD Giovanni Appendino, PhD Professor of Ophthalmology, Mt. Sinai Professor of Ophthalmology, Mt. Sinai Professor of Organic Chemistry, U. • Shelley and Steven Einhorn • Professor Ophthalmology, Icahn School Piedmont Distinguished Professo
Slide 22: Investment Highlights: Finance Dashboard
\INVESTMENT HIGHLIGHTS 1 2 FINANCE DASHBOARD 476.1M 5.2M Common Shares Outstanding Convertible Debt Shares 3 $18.1M Market Cap 1 1 178.1M 659.4M Options & Warrants Fully Diluted 1 Based on prospectus filed 9/28/21 2 Based on principal balance and accrued interest outstanding as of 21/03/31 on multi-
Slide 23: Investment Highlights – Skye Summary
INVESTMENT HIGHLIGHTS SKYE SUMMARY • Near-term initiation of SBI-100 Phase 1 safety and tolerability study • Key nonclinical studies have established mechanism of q Building organization action and efficacy of SBI-100 in glaucoma q Finalizing nonclinical studies q Complete Phase 1 • Skye’s near-term
Slide 24: Thank You
THANK YOU To learn more please contact: Punit Dhillon Chief Executive Officer & Chair ir@skyebioscience.com 1 (858) 410-0266
Skye Bioscience — Investor Presentation (February 2022) on 6ix